New hope for advanced cancer patients with HER-2 tumors
NCT ID NCT07387874
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the safety of a drug called trastuzumab rezetecan, given alone or with other treatments, for people with advanced solid tumors that have the HER-2 protein. About 30 adults whose cancer has come back or spread, and who have not responded to or cannot take standard therapies, will be enrolled. The main goal is to track serious side effects, while also measuring how well the drug shrinks tumors and delays cancer growth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
BeidahuangGGH
Harbin, China